Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb
Primary Purpose
Ischemic Ulcer
Status
Completed
Phase
Phase 1
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
4times injection
stem cell transplantation
Sponsored by

About this trial
This is an interventional treatment trial for Ischemic Ulcer focused on measuring bone marrow mono nuclear stem cell ischemic ulcer
Eligibility Criteria
Inclusion Criteria:
- Ischemic lower limb based on TASK guide line
- Rutherford score:2,3
- ABI<0.6
- Absolute ankle pressure < 60 mmHg
- Both gender
- Age:20-62years
Exclusion Criteria:
- EF<30%
- Cr>2
- HbA1c>8%
- Bone marrow disorders:leukemia
- Cognitive disorders
- Infections
- MI with ST elevation during last month
- Malignancy
- Immunologic or rheumatologic disorders
Sites / Locations
- Royan Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
4times injection
one injection
Arm Description
the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
Patients with peripheral artery disease underwent cell transplantation just one time.
Outcomes
Primary Outcome Measures
side effects
evaluation the side effect of cell injection like:allergic reaction,fever,skin eruption,pain increasing,decrease in walking distance,ulcer severity
Secondary Outcome Measures
PFWD
Evaluation the pain free walking distance after cell transplantation.
ABI
evaluation the improvement the score of ABI after stem cell transplantation .
size and depth of ulcer
evaluation the improvement of ulcer by measuring the size and depth of ulcer in millimeter after transplantation.
Amputation
Evaluation the need of limb amputation because of worsening the ulcer after cell injection.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01480414
Brief Title
Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb
Official Title
Evaluation the Side Effects of Repeated Bone Marrow Derived Mono Nuclear Stem Cells Transplantation in Patients With Lower Limb Ischemic Ulcer
Study Type
Interventional
2. Study Status
Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
May 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royan Institute
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Critical limb ischemia (CLI) results from severe occlusive disease that impairs distal limb perfusion to the point where oxygen delivery is no longer adequate to meet the metabolic needs of the tissue, even under resting conditions. The limits of peripheral artery disease (PAD) compensatory mechanisms, such as distal vasodilatation and collateral formation, have been exceeded at this point. PAD is a widespread disease, affecting up to 15% of all adults older than 55 years. Formation of true new blood vessels, or angiogenesis, and development of collateral vessels from preexisting blood vessels, or arteriogenesis, is important in the pathophysiology of vascular disease. By stimulating these processes the investigators might be able to provide an alternative treatment strategy for patients with lower limb ischemia. In response to tissue injury and remodeling, neovascularization usually occurs via the proliferation and migration of progenitor endothelial cells (EPC) from preexisting vasculature. Indeed, recent studies have shown that bone-marrow mononuclear cell (BM-MNC) implantation increases collateral vessel formation in patients with limb ischemia. So the investigators determine to evaluate the efficacy of repeated MNC transplantation in patients with ischemic lower limb.
Detailed Description
In this study we transparent bone marrow derived mononuclear stem cells 4 times to the ischemic limb of 11 patients with PAD.first of all all the patients evaluate by physical examination,PFWD,ABI and serologic tests.then underwent bone marrow aspiration to take sample.In our lab the MNC are separated and divided in to equal doses.one of them inject to the ischemic foot and the othr one are freezed and inject after 3weeks.3 weeks after second injection again patient underwent bone marrow aspiration and the same process repeat.then after 4times transplantation,patients are followed up after 1,3,6,9,12 months after injection and evaluate by physical examination,PFWD,ABI and serologic tests.all the data are collected and analysed and the result will be shown.3 patients underwent cell transplantation just one time due to one time bone marrow aspiration.They are followed up after 1,3,6,9,12 months after injection and evaluate by physical examination,PFWD,ABI and serologic tests.at the end of the study patients with 4imes injection and 1time injection will be compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Ulcer
Keywords
bone marrow mono nuclear stem cell ischemic ulcer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
4times injection
Arm Type
Experimental
Arm Description
the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
Arm Title
one injection
Arm Type
Experimental
Arm Description
Patients with peripheral artery disease underwent cell transplantation just one time.
Intervention Type
Biological
Intervention Name(s)
4times injection
Intervention Description
bone marrow derived mono nuclear stem cell
Intervention Type
Biological
Intervention Name(s)
stem cell transplantation
Intervention Description
Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
Primary Outcome Measure Information:
Title
side effects
Description
evaluation the side effect of cell injection like:allergic reaction,fever,skin eruption,pain increasing,decrease in walking distance,ulcer severity
Time Frame
3months
Secondary Outcome Measure Information:
Title
PFWD
Description
Evaluation the pain free walking distance after cell transplantation.
Time Frame
3months
Title
ABI
Description
evaluation the improvement the score of ABI after stem cell transplantation .
Time Frame
3months
Title
size and depth of ulcer
Description
evaluation the improvement of ulcer by measuring the size and depth of ulcer in millimeter after transplantation.
Time Frame
3months
Title
Amputation
Description
Evaluation the need of limb amputation because of worsening the ulcer after cell injection.
Time Frame
6months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
62 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ischemic lower limb based on TASK guide line
Rutherford score:2,3
ABI<0.6
Absolute ankle pressure < 60 mmHg
Both gender
Age:20-62years
Exclusion Criteria:
EF<30%
Cr>2
HbA1c>8%
Bone marrow disorders:leukemia
Cognitive disorders
Infections
MI with ST elevation during last month
Malignancy
Immunologic or rheumatologic disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hamid Gourabi, PhD
Organizational Affiliation
Head of Royan Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
mohammad zafarghandi, MD
Organizational Affiliation
surgery scientist
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Nasser Aghdami, MD,PhD
Organizational Affiliation
head of Royan cell therapy center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Behnam Molavi, MD
Organizational Affiliation
Surgery scientist
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royan Institute
City
Tehran
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
27293053
Citation
Molavi B, Zafarghandi MR, Aminizadeh E, Hosseini SE, Mirzayi H, Arab L, Baharvand H, Aghdami N. Safety and Efficacy of Repeated Bone Marrow Mononuclear Cell Therapy in Patients with Critical Limb Ischemia in a Pilot Randomized Controlled Trial. Arch Iran Med. 2016 Jun;19(6):388-96.
Results Reference
derived
Learn more about this trial
Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb
We'll reach out to this number within 24 hrs